Protein kinases have proven to be a major drug target with over 20 kinase inhibitors approved for the treatment of cancers and inflammatory diseases in the past 20 years. The human kinome comprises 518 known protein kinases and approximately 20 lipid kinases. Nearly all aspects of cell life are controlled by reversible phosphorylation of proteins mediated by protein kinases and abnormal phosphorylation is a cause or effect of many diseases. As a consequence many pharma and biotech companies continue to undertake primary screening against kinase targets believed to be clinically important. A significant step in the optimization of a kinase lead is the determination of the comparative selectivity of those leads against other kinase enzymes. This so-called kinase profile is typically performed against a panel of kinase enzymes. This approach has facilitated the development of inhibitors with enhanced potency against the selected kinase(s) targets. In addition, it may result in the identification of possible novel selectivity against unexpected kinase targets. Up until a few years ago the typical kinase panel may have been drawn from closely-related members of the kinase super family with occasional representation from other families. However, the current trend is towards wider profiling against a more comprehensive kinase panel, in some cases utilizing all available kinases. This has led to competition among fee-for-service providers as to who can offer the broadest panel, with new kinases being added to their panel at almost weekly intervals. The ability to profile against the widest possible panel of kinases in house involves considerable expense and resources which few organizations can afford today. As a consequence outsourcing of kinase profiling is now the accepted practice, particularly if a broad kinome profile is wanted. As more pharma companies focus on the screening of related target families in parallel across therapeutic area boundaries, greater importance is being given to the early determination of selectivity profiling. This has contributed to the increasing number of companies that now offer outsourced kinase profiling on a fee-for-service basis.
With over 15 years of experience, DiscoverX’s KINOMEscan® platform employs a proprietary active site-directed competition binding assay to quantitatively measure interactions between test compounds and kinases across more than 480 assays, the largest collection available. With the fastest turnaround time and broad dynamic range, KINOMEscan® services enable expedited SAR analysis.
"Kinome-wide broad profiling with KINOMEscan® enables extensive annotation of compounds with accurate, reproducible data in order to leverage existing chemical assets to jumpstart new discovery programs"
Daniel Treiber, Ph.D., Chief Technology Officer, Drug Discovery Services, DiscoverX CorporationMore Information
In May 2016 HTStec undertook a market survey on kinase profiling mainly among research labs in pharma, biotech and academia. The survey was initiated by HTStec as part of its tracking of life science marketplaces and to update HTStec's previous kinase profiling trends report (published May 2013). The objective was to comprehensively document current practices and preferences in kinase profiling, and to understand future user requirements, particularly with respect to the cost and use of outsourced services. The aim was to compile a reference document on kinase profiling metrics, which could be compared directly relative to HTStec’s previous 2013 report. This article contains ‘selected findings’ from the HTStec market report, Kinase Profiling Trends 2016. It is intended to provide the reader with a brief insight into recent market trends. It covers only 11 out of the 30 original questions detailed in the full report. In this ‘selected findings’ we focus our discussion exclusively on outsourced kinase profiling, although the market report on which it was based did also examine in house profiling. The full published report should be consulted to view the entire dataset, details of the breakdown of the responses for each question, its segmentation and the estimates for the future. Please click here for more information.
Around 2/3rd of all kinase profiling activities are outsourced today. The main therapeutic areas utilizing the results of these outsourced kinase profiling assays are given in Figure 1. This showed that the majority (80%) of survey respondents were using kinase assays within the oncology therapeutic area (TA). This was followed by 44% in the inflammatory disease/autoimmune TA; 26% neurology TA; 19% metabolic assays; 11% cardiovascular and anti-infective TA’s; and 9% other TA’s.
Preferred outsourced kinase panel profiling assay formats:
The preferred outsourced kinase panel profiling assay formats are presented in Figure 2. This showed that the preferred first choice outsourced kinase panel profiling assay format wanted by the majority (68%) was activity assays (e.g. Reaction Biology’s HotSpot radiolabeled activity based kinase assays). This was followed by binding assays (23%) and then cellular assays (8%). The preferred second choice outsourced kinase panel profiling assay format wanted by most was equally split between cellular-based assays (37%) and binding assays (35%), and then activity-based assays (27%).
Typical use of outsourced kinase panel profiling services:
The total number of wells profiled against kinase panels per year at outsourced providers are detailed in Figure 3. This showed that the median total number of single wells/year tested at outsourced kinase panel profiling providers was 500-5K wells/year in 2016.
The breakdown of kinase profiling wells outsourced in 2016 are reported in Figure 4. This showed that most (33%) outsourced kinase profiling wells were duplicate or replicate point (% inhibition) tests (n>1). This was followed by single point response curve (IC50s or Kds) tests (n=1) (27%); duplicate or replicate point response curve (IC50s or Kds) tests (n>1) (22%); and then single point (% inhibition) tests (n=1) (18%).
Choosing a kinase profiling panel:
The size of the outsourced kinase panels used in 2016 for SAR in lead optimization or at final decision stage (prior to candidate selection) are given in Figure 5. This showed that the median size of kinase panels outsourced for SAR in lead optimization was 50-100 kinases, versus 100-150 kinases at the final decision stage.
The size of kinase profiling panel respondents would prefer an outsourced provider to offer is presented in Figure 6. This showed that the median preferred size of a kinase panel offered by an outsourced provider was 200-300 kinases. Although the greatest proportion of respondents (36%) wanted >400 kinases i.e. as much of the kinome represented as is possible.
The number of disease-relevant mutant kinases respondents would like to see represented in an outsourced provider’s kinase panel is detailed in Figure 7. This showed that a median of 1-50 disease-relevant mutant kinases were wanted in an outsourced panel.
When respondents would choose to do a broad kinome profile for selectivity and off-target interactions is reported in Figure 8. This showed that the majority (55%) would choose to do a broad kinome profile during lead optimization. A further 35% would do it before final candidate selection, 6% would never choose it, and 4% would do it after final candidate selection.
Choosing kinase profiling panel provider:
Survey respondents were asked to choose their most preferred providers of outsourced kinase panel profiling. The preferences recorded as the percentage share of all provider selections are summarised in Figure 9. This showed that Reaction Biology was the most preferred outsourced kinase panel profiling fee-for-service provider with 31% share of the selections. This was followed by DiscoverRx (16%), Eurofins (11%) and Thermo Fisher Scientific (10%). All other vendors had 5% or less share of selections. Please Note: this a not a true market share based on actual purchasing of services, but rather a summation of the number of preferences respondents made for a particular service provider.
The decision-making criteria that were rated most important when selecting an outsourced kinase service provider are listed in Figure 10. This showed that high-quality reproducible data was rated most highly with 73% of survey respondents selecting. This was followed by cost per assay (66%), turnaround time (62%), breadth of kinase offering (i.e. panel size) (47%), and then assay format (i.e. functional/binding; fluorescent/radiolabel) (44%). The least important criteria when selecting an outsourced kinase service provider were ability to purchase products/technology used in the service, and informatics and innovative data visualization tools.
Where respondents think kinase service providers should focus their efforts going forward is detailed in Figure 11. This showed that most (46%) wanted to see cell-based assays based on endogenous kinase expression (more physiological relevant). This was followed by lowering price (44%), cell-based assays based on overexpressed kinases (27%); increasing the number of kinases offered (24%), and then improving data quality (24%). Considered least wanted were cross-species assay development and providing better customer support.
The selected findings reported above have shown that oncology was the main therapeutic area utilizing the results of these outsourced kinase profiling assays. Activity assays were the preferred outsourced kinase panel profiling assay format. A median of 500-5,000 single assay wells per year are outsourced to kinase panel profiling providers. Most of these outsourced wells were duplicate or replicate point (% inhibition) tests (n>1). The median size of kinase panels outsourced for SAR in lead optimization was 50-100 kinases, versus 100-150 kinases at the final decision stage. The median preferred size of a kinase panel offered by an outsourced provider was 200-300 kinases. A median of 1-50 disease-relevant mutant kinases were wanted in an outsourced panel. The majority would choose to do a broad kinome profile during lead optimization. Reaction Biology was the most preferred outsourced kinase panel profiling fee-for-service provider. High-quality reproducible data was rated the most important decision-making criteria when selecting an outsourced kinase service provider. Cell-based assays based on endogenous kinase expression (more physiological relevant) are where respondents think kinase service providers should focus their efforts going forward.
Maximizing assay representation across the entire kinome including wild type, mutant, atypical, lipid and pathogen kinases has been a major objective of nearly all fee-for-service providers over recent years. The total number of kinases available for outsourced profiling now exceeds 600 at some providers. Many providers have also greatly improved their data delivery times to only a few days in some cases. In addition, some providers are now offering novel cell-based assay formats to validate kinase inhibitors e.g. 3D tumor spheroid assays; soft agar/clonogenic assays; cell-based tyrosine kinase assays; direct quantification of specific kinase phosphorylation activity in human cells; to name a few. With a large number of providers competing for business assay services pricing has never been keener. However, customer requirements are never 100% matched and end-users can always find unmet needs, here are just some of those few reported to us: 1) greater flexibility in the ability to customize panels without costs spiralling; 2) assays to be available in the same format (there is currently no accepted universal detection method); 3) better analysis of the kinase relationships across the entire kinome; 4) more cell-based panels at a reasonable cost; 5) consistent naming of enzyme/protein and information provided by the different suppliers; 6) a platform to evaluate inactive kinases; 7) binding kinetics data e.g. koff rates, and 8) greater clarity over the activation-state of the kinase being profiled. Despite these shortcomings the case for outsourcing kinase profiling versus in house testing has never been better served.
John Comley is Managing Director of HTStec Limited.
DISCLAIMER: HTStec Limited has exercised due care in compiling and preparing these Selected Findings from its Report, which is based on information submitted by individuals in respondent companies. HTStec Limited has NOT verified the accuracy of this information, nor has it is established respondent’s authority to disclose information to HTStec Limited. HTStec Limited expressly disclaims any and all warranties concerning these Selected Findings including any warranties of mechantability and/or fitness for any particular purpose, and warranties of performance, and any warranty that might otherwise arise from course of dealing or usage of trade. No warranty is either expressed or implied with respect to the use of these Selected Findings. Under no circumstances shall HTStec Limited be liable for incidental, special, indirect, direct or consequential damages or loss of profits, interruption of business, or related expenses that may arise from use of these Selected Findings, including but not limited to those resulting from inaccuracy of the data therein.
Microfluidic Method Identifies Rare Antibodies with Therapeutic PotentialArticle
A novel microfluidic platform, able to rapidly isolate and identify rare antibodies from a vast repertoire of human B cells, has been developed by scientists. This technology could possess the ability to support and enhance the development of novel vaccines and biopharmaceuticals in the future.READ MORE
Promoting the Use of AI within the Life Sciences IndustryArticle
Awareness of Artificial Intelligence (AI), Machine Learning (ML) and Neuro-linguistic Programming (NLP) is ever-increasing, with AI being one of the most talked about technologies across multiple industries. The Pistoia Alliance recently surveyed 374 life science professionals to determine the impact of AI, ML and NLP on the life sciences industry.READ MORE
The Viral Genome: Moving Beyond Reading Code – Why Not Rewrite It?Article
Researchers have discovered how to read, decode, and manipulate previously ‘hidden’ viral code. This could open up new opportunities in drug delivery and gene therapy.READ MORE